Technology
Health
Biotechnology

Soligenix

$0.725
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0227 (-2.98%) Today
-$0.0131 (-1.77%) After Hours

Why Robinhood?

You can buy or sell Soligenix and other stocks, options, ETFs, and crypto commission-free!

About

Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. Read More The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.

Employees
14
Headquarters
Princeton, New Jersey
Founded
1987
Market Cap
13.05M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
184.40K
High Today
$0.80
Low Today
$0.69
Open Price
$0.76
Volume
53.66K
52 Week High
$2.20
52 Week Low
$0.6501

Collections

Technology
Health
Biotechnology
Therapy
2016 IPO
US
North America

News

PR NewswireApr 23

Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

PRINCETON, N.J., April 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below. Dear Friends and Shareholders, I wanted to take this opportunity to provide an update, as well as to...

237

Earnings

-$0.27
-$0.18
-$0.09
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.09 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.